Jocelyn Jansen van Vuuren
Biographic Data
| ID | 9075692 |
|---|---|
| NAME | Jocelyn Jansen van Vuuren |
| GIVEN NAMES | Jocelyn Jansen |
| FAMILY NAME | van Vuuren |
| SIGNATURE | VAN VUUREN J J |
| AFFILIATIONS | Médecins Sans Frontières |
| ORCID | 0009-0000-9737-8664 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort
Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complica…
No prominent works on this page.
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort
Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complica…
Adverse effect (1 work) · Cohort (1 work) · Cohort study (1 work) · Drug-Induced Hepatotoxicity and Protection (1 work) · Hepatitis C (1 work) · Hepatitis C virus (1 work) · Hepatitis C virus research (1 work) · Immunology (1 work) · Internal Medicine (1 work) · Medicine (1 work)